AstraZeneca Plc (AZN, AZN.L) reported positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related pain and opioid-induced constipation, or OIC. These Phase III KODIAC trials assessed the safety and efficacy of naloxegol, an oral peripherally-acting, mu-opioid receptor antagonist for the treatment of OIC, a common side effect of prescription opioids.
KODIAC-04 and -05 are both multicenter, randomized, double-blind, placebo-controlled pivotal trials of 12 weeks duration evaluating 12.5 mg and 25 mg naloxegol administered once-daily. The primary endpoint in both trials was percentage of OIC responders versus placebo over 12 weeks of treatment where a responder was defined as having at least three Spontaneous Bowel Movements, or SBM, per week, with at least one SBM per week increase over baseline, for at least nine out of 12 weeks, and at least three out of the last four weeks.
Under the design of both trials, statistical significance for the primary endpoint would be achieved if at least one of the two naloxegol doses had a p-value <0.025 compared="" with="">
Analysis of the data indicates that in KODIAC-04 both naloxegol doses (12.5 mg and 25 mg) demonstrated statistically significant results for the primary endpoint. P-values were 0.015 and 0.001 respectively.
In KODIAC-05, the 25 mg dose demonstrated a statistically significant result for the primary endpoint but the 12.5 mg dose did not. P-values were 0.202 for 12.5 mg and 0.021 for 25 mg. Further, the analyses showed no clinically relevant imbalances in serious adverse events, including externally adjudicated major cardiovascular events, across the three treatment arms in KODIAC-04, -05 and -07.
by RTTNews Staff Writer
For comments and feedback: editorial@rttnews.com